Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC By Ogkologos - September 8, 2026 44 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NSABP B-59/GeparDouze study Source RELATED ARTICLESMORE FROM AUTHOR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce MOST POPULAR Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer May 12, 2021 Pruebas genéticas para el cáncer en familias: Preguntas y respuestas con... May 19, 2022 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 Happy 29th Birthday OncoLink! March 7, 2023 Load more HOT NEWS Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... 7 Steps for Developing Microhabits During Cancer That Can Improve Your... Waiting for Insurance to Cover Her Mammogram Could Have Cost This... ESMO Calls for Cancer Care Integration in EU Global Health Resilience...
